TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07899996: A Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of HB0056 in Adult Participants With Moderate to Severe Asthma

Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 160 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$9,384,000

Rescue Site Savings

+$6,187,575

Unlock Full NCT07899996 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07899996 Rescue Dossier →